Published in S Afr Med J on October 24, 1981
A case-control comparison of the results of renal transplantation from heart-beating and non-heart-beating donors. Transplantation (2001) 1.52
Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol (1987) 1.36
An algorithm for the management of bile leak following laparoscopic cholecystectomy. Ann R Coll Surg Engl (2007) 1.20
Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost (1986) 1.09
Quantitation of in vivo platelet aggregation by the platelet aggregate ratio method. Thromb Res (1977) 1.04
Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol (1989) 1.01
Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology (1984) 0.97
Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacology (1986) 0.91
Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. J Pharmacol Exp Ther (1988) 0.85
In vitro and in vivo pharmacological profiles of the PAF receptor antagonist SRI 63-675. Thromb Haemost (1987) 0.85
Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. Immunopharmacology (1986) 0.84
Evaluation of platelet-inhibiting drugs in models of atherosclerosis. Annu Rev Pharmacol Toxicol (1982) 0.84
Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol (1986) 0.82
Antiplatelet activity of hydralazine. Thromb Res (1979) 0.80
Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig. Prostaglandins Leukot Med (1986) 0.80
Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology (1987) 0.80
Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb Haemost (1984) 0.79
Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. Transplantation (1987) 0.78
Increased vascular resistance by prostaglandins B 1 and B 2 in the isolated rat pancreas. Nat New Biol (1972) 0.78
Changes in vascular resistance induced by prostaglandins E 2 and F 2 in the isolated rat pancreas. Arch Int Pharmacodyn Ther (1972) 0.78
Evaluation of the effect of a platelet activating factor antagonist on platelet activating factor and Ascaris antigen-induced airway responses in rhesus monkeys. J Lab Clin Med (1987) 0.77
Inhibition by SRI 63-072 and SRI 63-119 of PAF-acether and immune complex effects in the guinea pig. Eur J Pharmacol (1987) 0.77
Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil. Artery (1983) 0.77
Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. Thromb Haemost (1985) 0.77
Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant Proc (2001) 0.76
Prospective study of routine contrast radiology after total gastrectomy (Br J Surg 2004; 91: 1015-1019). Br J Surg (2004) 0.75
Assessment of diabetogenic drug activity in the rat: 5,5-diphenyl-2-thiohydantoin. J Toxicol Environ Health (1977) 0.75
Stimulation of DOPA14C incorporation into melanoma tissue by chlorpromazine and reserpine. Toxicol Appl Pharmacol (1970) 0.75
Influence of 1,3-butanediol on blood glucose concentration and pancreatic insulin content of streptozotocin-diabetic rats. Fed Proc (1975) 0.75
Assessment of diabetogenic drug activity in the rat: diphenylhydantoin. J Toxicol Environ Health (1976) 0.75
The biological properties of aspartame. V. Effects on a variety of physiological parameters related to inflammation and metabolism. J Environ Pathol Toxicol (1981) 0.75
A randomized trial of mycophenolate mofetil versus azathioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy. Transplant Proc (2002) 0.75
Synthesis and biological activities of arachidonic and alpha- and beta-alkyl-substituted arachidonic acid derivatives. Adv Prostaglandin Thromboxane Res (1980) 0.75
Long-term results of renal transplantation using organs from non-heart-beating donors. Transplant Proc (2001) 0.75
Quality of life for renal transplant recipients of organs from non-heart-beating donors, heart-beating cadaveric donors, and living-related donors. Transplant Proc (2001) 0.75
Normothermic perfusion of ischaemically damaged porcine kidneys: an evaluation of ex vivo function. Transplant Proc (2001) 0.75
The challenge of finding donors. Practitioner (2001) 0.75
Current status of drugs used to treat hyperlipoproteinemias. Drug Ther (1982) 0.75
Measuring intrarenal vascular resistance during machine perfusion preservation does not improve the assessment of renal viability made on clinical grounds. Transplant Proc (2001) 0.75
Effects of combined receptor antagonists of leukotriene D4 (LTD4) and platelet-activating factor (PAF) on rhesus airway responses to LTD4, PAF and antigen. Int Arch Allergy Appl Immunol (1989) 0.75
Metabolism cage for carbon dioxide trapping studies. J Toxicol Environ Health (1977) 0.75
Platelets and atherosclerosis. Prog Drug Res (1985) 0.75
In vivo effect of suloctidil as an antiplatelet agent. Thromb Haemost (1979) 0.75
The retired breeder rat as a new model for antiplatelet drug discovery. Lab Anim Sci (1977) 0.75
Effects of SC-26096(2-methyl-3-oxo-2azabicyclo(2.2.2.)octan-6-exo-yl 5-(4-biphenylyl)-3-methyl valerate), a new hypolipidemic agent, on mitochondrial respiration and oxidative phosphorylation. Biochem Pharmacol (1974) 0.75